Allogene Therapeutics (ALLO) Other Accumulated Expenses (2017 - 2025)

Allogene Therapeutics has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $2.4 million for Q4 2025.

• Other Accumulated Expenses for Q4 2025 came in at $2.4 million, up 123.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 million (up 123.6% YoY), and the FY2025 annual result was $2.4 million, up 123.6% from the prior year.
• Other Accumulated Expenses came in at $2.4 million for Q4 2025 at Allogene Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.4 million in Q4 2025 to a low of $1.1 million in Q4 2024.
• The 5-year median for Other Accumulated Expenses is $1.8 million (2023), against an average of $1.8 million.
• Across the five-year window, Other Accumulated Expenses sank 63.58% in 2021 and surged 123.6% in 2025, its largest moves.
• Allogene Therapeutics' Other Accumulated Expenses stood at $1.7 million in 2021, then gained by 21.38% to $2.1 million in 2022, then dropped by 14.59% to $1.8 million in 2023, then plunged by 40.74% to $1.1 million in 2024, then soared by 123.6% to $2.4 million in 2025.
• The last three Other Accumulated Expenses figures came in at $2.4 million (Q4 2025), $1.1 million (Q4 2024), and $1.8 million (Q4 2023), per Business Quant data.